M Klemsz

3.8k total citations · 1 hit paper
17 papers, 2.8k citations indexed

About

M Klemsz is a scholar working on Molecular Biology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, M Klemsz has authored 17 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 7 papers in Immunology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in M Klemsz's work include Ubiquitin and proteasome pathways (5 papers), T-cell and B-cell Immunology (4 papers) and Sarcoma Diagnosis and Treatment (3 papers). M Klemsz is often cited by papers focused on Ubiquitin and proteasome pathways (5 papers), T-cell and B-cell Immunology (4 papers) and Sarcoma Diagnosis and Treatment (3 papers). M Klemsz collaborates with scholars based in United States, France and Spain. M Klemsz's co-authors include R. Maki, Robert Hromas, Scott R. McKercher, Sujatha Nagulapalli, Christopher J. Paige, G E Wu, Ann J. Feeney, Hélène Baribault, Bruce E. Torbett and Gregory W. Henkel and has published in prestigious journals such as Science, Journal of Biological Chemistry and The Journal of Experimental Medicine.

In The Last Decade

M Klemsz

17 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities.

1996 896 citations Scott R. McKercher, Bruce E. Torbett et al. The EMBO Journal profile →

Peers

Countries citing papers authored by M Klemsz

Since Specialization

Citations

This map shows the geographic impact of M Klemsz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Klemsz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Klemsz more than expected).

Fields of papers citing papers by M Klemsz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M Klemsz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Klemsz. The network helps show where M Klemsz may publish in the future.

Co-authorship network of co-authors of M Klemsz

This figure shows the co-authorship network connecting the top 25 collaborators of M Klemsz. A scholar is included among the top collaborators of M Klemsz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M Klemsz. M Klemsz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	A Phase One, Open Label, Multi-Dose Study To Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients with Idiopathic Pulmonary Fibrosis (IPF) 2013 ·The Journal of Heart and Lung Transplantation ·(unknown), (unknown), (unknown), M Klemsz, (unknown), David S. Wilkes	2
2	53 PU.1 Expression Delineates Heterogeneity in Primary Th2 Cells 2006 ·Pediatric Research ·Hua‐Chen Chang, (unknown), Vivian T. Thieu, Roger B. Slee, Heather A. Bruns, R. Nicholas Laribee, M Klemsz, (unknown)	2
3	Isolation and characterization of Exodus-2, a novel C-C chemokine with a unique 37-amino acid carboxyl-terminal extension 1997 ·The Journal of Immunology ·Robert Hromas, Chang H. Kim, M Klemsz, Mitchell D. Krathwohl, K H Fife, Stephanie Cooper, Carol Schnizlein‐Bick, H E Broxmeyer	125
4	Hematopoietic Transcriptional Regulation by the Myeloid Zinc Finger Gene, MZF-1 1996 ·Current topics in microbiology and immunology ·Robert Hromas, Brian R. Davis, F. J. Rauscher, M Klemsz, Daniel G. Tenen, Susan M.G. Hoffman, Dawei Xu, (unknown)	80
5	Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. breakdown → 1996 ·The EMBO Journal ·Scott R. McKercher, Bruce E. Torbett, Kenton L. Anderson, Gregory W. Henkel, Deborah J. Vestal, Hélène Baribault, M Klemsz, Ann J. Feeney, G E Wu, Christopher J. Paige, R. Maki	896
6	The transcription factor PU.1 is involved in macrophage proliferation. 1996 ·The Journal of Experimental Medicine ·Antonio Celada, Francesc E. Borràs, Concepció Soler, Jorge Lloberas, M Klemsz, Charles Van Beveren, Scott R. McKercher, Richard A. Maki	132
7	The ETS oncogene family in development, proliferation and neoplasia. 1994 ·PubMed ·Robert Hromas, M Klemsz	48
8	Genes associated with immunoglobulin V(D)J recombination are linked on mouse chromosome 2 and human chromosome 11 1993 ·Immunogenetics ·Konrad Hüppi, David Siwarski, John D. Shaughnessy, M Klemsz, Masaki Shirakata, Richard A. Maki, Hitomi Sakano	4
9	Effect of PU.1 phosphorylation on interaction with NF-EM5 and transcriptional activation 1993 ·Science ·(unknown), Charles Van Beveren, Sujatha Nagulapalli, M Klemsz, (unknown), R. Maki, Michael L. Atchison	254
10	The Ewing’s Sarcoma EWS/FLI-1 Fusion Gene Encodes a More Potent Transcriptional Activator and is a More Powerful Transforming Gene than FLI-1 1993 ·Molecular and Cellular Biology ·William A. May, Stephen L. Lessnick, Benjamin S. Braun, M Klemsz, (unknown), Lynn Lunsford, Robert Hromas, Christopher T. Denny	121
11	Characterization of the ets oncogene family member, fli-1. 1993 ·Journal of Biological Chemistry ·M Klemsz, Richard A. Maki, T Papayannopoulou, Jason H. Moore, Robert Hromas	82
12	Hematopoietic lineage- and stage-restricted expression of the ETS oncogene family member PU.1 1993 ·Blood ·Robert Hromas, Attilio Orazi, RS Neiman, Richard A. Maki, (unknown), Jason H. Moore, M Klemsz	183
13	Drosophila forkhead homologues are expressed in a lineage-restricted manner in human hematopoietic cells 1993 ·Blood ·Robert Hromas, Jason H. Moore, Thomas Johnston, (unknown), M Klemsz	1
14	The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. 1993 ·Molecular and Cellular Biology ·Win May, Stephen L. Lessnick, Benjamin S. Braun, M Klemsz, Brian C. Lewis, Lynn Lunsford, Robert Hromas, Christopher T. Denny	399
15	Drosophila forkhead homologues are expressed in a lineage-restricted manner in human hematopoietic cells 1993 ·Blood ·Robert Hromas, Jason H. Moore, Thomas Johnston, (unknown), M Klemsz	30
16	PU.1 recruits a second nuclear factor to a site important for immunoglobulin kappa 3' enhancer activity. 1992 ·Molecular and Cellular Biology ·Jagan M.R. Pongubala, Sujatha Nagulapalli, M Klemsz, Scott R. McKercher, R. Maki, Michael L. Atchison	320
17	Induction of c-fos and c-myc expression during B cell activation by IL-4 and immunoglobulin binding ligands. 1989 ·The Journal of Immunology ·M Klemsz, Louis B. Justement, Ed Palmer, John C. Cambier	80

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact